nodes	percent_of_prediction	percent_of_DWPC	metapath
Vinorelbine—Vinca Alkaloids—Vincristine—lymphatic system cancer	0.361	1	CiPCiCtD
Vinorelbine—Vincristine—lymphatic system cancer	0.273	1	CrCtD
Vinorelbine—Vindesine—Vincristine—lymphatic system cancer	0.064	0.379	CrCrCtD
Vinorelbine—Vinblastine—Vincristine—lymphatic system cancer	0.064	0.379	CrCrCtD
Vinorelbine—Voacamine—Vincristine—lymphatic system cancer	0.0409	0.242	CrCrCtD
Vinorelbine—TUBB4A—Vincristine—lymphatic system cancer	0.0182	0.112	CbGbCtD
Vinorelbine—TUBB2B—Vincristine—lymphatic system cancer	0.0182	0.112	CbGbCtD
Vinorelbine—TUBB3—Vincristine—lymphatic system cancer	0.0182	0.112	CbGbCtD
Vinorelbine—TUBB8—Vincristine—lymphatic system cancer	0.0182	0.112	CbGbCtD
Vinorelbine—TUBB6—Vincristine—lymphatic system cancer	0.0182	0.112	CbGbCtD
Vinorelbine—TUBB2A—Vincristine—lymphatic system cancer	0.0182	0.112	CbGbCtD
Vinorelbine—TUBB4B—Vincristine—lymphatic system cancer	0.0152	0.0937	CbGbCtD
Vinorelbine—TUBB1—Vincristine—lymphatic system cancer	0.0152	0.0937	CbGbCtD
Vinorelbine—TUBB—Vincristine—lymphatic system cancer	0.0152	0.0937	CbGbCtD
Vinorelbine—ABCB1—Mitoxantrone—lymphatic system cancer	0.00157	0.00969	CbGbCtD
Vinorelbine—CYP3A4—Cytarabine—lymphatic system cancer	0.00137	0.00843	CbGbCtD
Vinorelbine—CYP3A4—Teniposide—lymphatic system cancer	0.00135	0.0083	CbGbCtD
Vinorelbine—ABCB1—Vincristine—lymphatic system cancer	0.00108	0.00667	CbGbCtD
Vinorelbine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.000941	0.00581	CbGbCtD
Vinorelbine—ABCB1—Methotrexate—lymphatic system cancer	0.000655	0.00404	CbGbCtD
Vinorelbine—CYP3A4—Vincristine—lymphatic system cancer	0.000648	0.004	CbGbCtD
Vinorelbine—TUBB6—Zalcitabine—Cytarabine—lymphatic system cancer	0.000263	0.403	CbGdCrCtD
Vinorelbine—TUBB—Azacitidine—Fludarabine—lymphatic system cancer	0.000142	0.217	CbGdCrCtD
Vinorelbine—TUBB—Azacitidine—Cytarabine—lymphatic system cancer	0.000134	0.205	CbGdCrCtD
Vinorelbine—TUBB6—Azacitidine—Fludarabine—lymphatic system cancer	5.86e-05	0.0897	CbGdCrCtD
Vinorelbine—TUBB6—Azacitidine—Cytarabine—lymphatic system cancer	5.53e-05	0.0848	CbGdCrCtD
Vinorelbine—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	4.63e-05	0.00131	CcSEcCtD
Vinorelbine—Nausea—Mechlorethamine—lymphatic system cancer	4.61e-05	0.00131	CcSEcCtD
Vinorelbine—Myocardial infarction—Mitoxantrone—lymphatic system cancer	4.6e-05	0.00131	CcSEcCtD
Vinorelbine—Alopecia—Bleomycin—lymphatic system cancer	4.59e-05	0.0013	CcSEcCtD
Vinorelbine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	4.58e-05	0.0013	CcSEcCtD
Vinorelbine—Stomatitis—Mitoxantrone—lymphatic system cancer	4.57e-05	0.0013	CcSEcCtD
Vinorelbine—Urticaria—Teniposide—lymphatic system cancer	4.55e-05	0.00129	CcSEcCtD
Vinorelbine—Abdominal pain—Teniposide—lymphatic system cancer	4.52e-05	0.00129	CcSEcCtD
Vinorelbine—Body temperature increased—Teniposide—lymphatic system cancer	4.52e-05	0.00129	CcSEcCtD
Vinorelbine—Erythema—Bleomycin—lymphatic system cancer	4.52e-05	0.00128	CcSEcCtD
Vinorelbine—Paraesthesia—Fludarabine—lymphatic system cancer	4.52e-05	0.00128	CcSEcCtD
Vinorelbine—Hypoaesthesia—Carmustine—lymphatic system cancer	4.51e-05	0.00128	CcSEcCtD
Vinorelbine—Dyspnoea—Fludarabine—lymphatic system cancer	4.48e-05	0.00127	CcSEcCtD
Vinorelbine—Connective tissue disorder—Carmustine—lymphatic system cancer	4.45e-05	0.00126	CcSEcCtD
Vinorelbine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	4.38e-05	0.00124	CcSEcCtD
Vinorelbine—Decreased appetite—Fludarabine—lymphatic system cancer	4.37e-05	0.00124	CcSEcCtD
Vinorelbine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	4.34e-05	0.00123	CcSEcCtD
Vinorelbine—Fatigue—Fludarabine—lymphatic system cancer	4.34e-05	0.00123	CcSEcCtD
Vinorelbine—Hypoaesthesia—Vincristine—lymphatic system cancer	4.3e-05	0.00122	CcSEcCtD
Vinorelbine—Pain—Fludarabine—lymphatic system cancer	4.3e-05	0.00122	CcSEcCtD
Vinorelbine—Constipation—Fludarabine—lymphatic system cancer	4.3e-05	0.00122	CcSEcCtD
Vinorelbine—Respiratory failure—Methotrexate—lymphatic system cancer	4.26e-05	0.00121	CcSEcCtD
Vinorelbine—Connective tissue disorder—Vincristine—lymphatic system cancer	4.25e-05	0.00121	CcSEcCtD
Vinorelbine—Hypersensitivity—Teniposide—lymphatic system cancer	4.22e-05	0.0012	CcSEcCtD
Vinorelbine—Flushing—Carmustine—lymphatic system cancer	4.2e-05	0.00119	CcSEcCtD
Vinorelbine—Ill-defined disorder—Bleomycin—lymphatic system cancer	4.19e-05	0.00119	CcSEcCtD
Vinorelbine—Pulmonary embolism—Methotrexate—lymphatic system cancer	4.18e-05	0.00119	CcSEcCtD
Vinorelbine—Anaemia—Bleomycin—lymphatic system cancer	4.18e-05	0.00119	CcSEcCtD
Vinorelbine—Feeling abnormal—Fludarabine—lymphatic system cancer	4.14e-05	0.00118	CcSEcCtD
Vinorelbine—Asthenia—Teniposide—lymphatic system cancer	4.11e-05	0.00117	CcSEcCtD
Vinorelbine—Malaise—Bleomycin—lymphatic system cancer	4.07e-05	0.00116	CcSEcCtD
Vinorelbine—Pruritus—Teniposide—lymphatic system cancer	4.05e-05	0.00115	CcSEcCtD
Vinorelbine—Arrhythmia—Carmustine—lymphatic system cancer	4.05e-05	0.00115	CcSEcCtD
Vinorelbine—Leukopenia—Bleomycin—lymphatic system cancer	4.04e-05	0.00115	CcSEcCtD
Vinorelbine—Cardiac disorder—Vincristine—lymphatic system cancer	4.01e-05	0.00114	CcSEcCtD
Vinorelbine—Alopecia—Carmustine—lymphatic system cancer	4e-05	0.00114	CcSEcCtD
Vinorelbine—Skin exfoliation—Methotrexate—lymphatic system cancer	3.99e-05	0.00113	CcSEcCtD
Vinorelbine—Body temperature increased—Fludarabine—lymphatic system cancer	3.98e-05	0.00113	CcSEcCtD
Vinorelbine—Malnutrition—Carmustine—lymphatic system cancer	3.94e-05	0.00112	CcSEcCtD
Vinorelbine—Erythema—Carmustine—lymphatic system cancer	3.94e-05	0.00112	CcSEcCtD
Vinorelbine—Cough—Bleomycin—lymphatic system cancer	3.94e-05	0.00112	CcSEcCtD
Vinorelbine—Angiopathy—Vincristine—lymphatic system cancer	3.92e-05	0.00111	CcSEcCtD
Vinorelbine—Aplastic anaemia—Methotrexate—lymphatic system cancer	3.92e-05	0.00111	CcSEcCtD
Vinorelbine—Diarrhoea—Teniposide—lymphatic system cancer	3.92e-05	0.00111	CcSEcCtD
Vinorelbine—Mediastinal disorder—Vincristine—lymphatic system cancer	3.9e-05	0.00111	CcSEcCtD
Vinorelbine—Chest pain—Bleomycin—lymphatic system cancer	3.85e-05	0.00109	CcSEcCtD
Vinorelbine—Myalgia—Bleomycin—lymphatic system cancer	3.85e-05	0.00109	CcSEcCtD
Vinorelbine—Alopecia—Vincristine—lymphatic system cancer	3.82e-05	0.00109	CcSEcCtD
Vinorelbine—Back pain—Carmustine—lymphatic system cancer	3.81e-05	0.00108	CcSEcCtD
Vinorelbine—Discomfort—Bleomycin—lymphatic system cancer	3.8e-05	0.00108	CcSEcCtD
Vinorelbine—Arrhythmia—Mitoxantrone—lymphatic system cancer	3.76e-05	0.00107	CcSEcCtD
Vinorelbine—Alopecia—Mitoxantrone—lymphatic system cancer	3.72e-05	0.00106	CcSEcCtD
Vinorelbine—Pulmonary oedema—Methotrexate—lymphatic system cancer	3.72e-05	0.00106	CcSEcCtD
Vinorelbine—Hypersensitivity—Fludarabine—lymphatic system cancer	3.71e-05	0.00105	CcSEcCtD
Vinorelbine—Anaphylactic shock—Bleomycin—lymphatic system cancer	3.69e-05	0.00105	CcSEcCtD
Vinorelbine—Erythema—Mitoxantrone—lymphatic system cancer	3.67e-05	0.00104	CcSEcCtD
Vinorelbine—Infection—Bleomycin—lymphatic system cancer	3.66e-05	0.00104	CcSEcCtD
Vinorelbine—Anaemia—Carmustine—lymphatic system cancer	3.65e-05	0.00104	CcSEcCtD
Vinorelbine—Back pain—Vincristine—lymphatic system cancer	3.64e-05	0.00103	CcSEcCtD
Vinorelbine—Vomiting—Teniposide—lymphatic system cancer	3.64e-05	0.00103	CcSEcCtD
Vinorelbine—Sepsis—Methotrexate—lymphatic system cancer	3.63e-05	0.00103	CcSEcCtD
Vinorelbine—Thrombocytopenia—Bleomycin—lymphatic system cancer	3.61e-05	0.00103	CcSEcCtD
Vinorelbine—Asthenia—Fludarabine—lymphatic system cancer	3.61e-05	0.00103	CcSEcCtD
Vinorelbine—Rash—Teniposide—lymphatic system cancer	3.61e-05	0.00103	CcSEcCtD
Vinorelbine—Dermatitis—Teniposide—lymphatic system cancer	3.6e-05	0.00102	CcSEcCtD
Vinorelbine—Headache—Teniposide—lymphatic system cancer	3.58e-05	0.00102	CcSEcCtD
Vinorelbine—Pruritus—Fludarabine—lymphatic system cancer	3.56e-05	0.00101	CcSEcCtD
Vinorelbine—Back pain—Mitoxantrone—lymphatic system cancer	3.55e-05	0.00101	CcSEcCtD
Vinorelbine—Leukopenia—Carmustine—lymphatic system cancer	3.53e-05	0.001	CcSEcCtD
Vinorelbine—Anorexia—Bleomycin—lymphatic system cancer	3.51e-05	0.000999	CcSEcCtD
Vinorelbine—Thrombophlebitis—Methotrexate—lymphatic system cancer	3.5e-05	0.000996	CcSEcCtD
Vinorelbine—Anaemia—Vincristine—lymphatic system cancer	3.48e-05	0.000989	CcSEcCtD
Vinorelbine—Polyuria—Methotrexate—lymphatic system cancer	3.45e-05	0.000981	CcSEcCtD
Vinorelbine—Hypotension—Bleomycin—lymphatic system cancer	3.45e-05	0.000979	CcSEcCtD
Vinorelbine—Diarrhoea—Fludarabine—lymphatic system cancer	3.44e-05	0.000978	CcSEcCtD
Vinorelbine—Hypertension—Carmustine—lymphatic system cancer	3.4e-05	0.000967	CcSEcCtD
Vinorelbine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	3.4e-05	0.000967	CcSEcCtD
Vinorelbine—Nausea—Teniposide—lymphatic system cancer	3.4e-05	0.000966	CcSEcCtD
Vinorelbine—Anaemia—Mitoxantrone—lymphatic system cancer	3.39e-05	0.000963	CcSEcCtD
Vinorelbine—Vertigo—Vincristine—lymphatic system cancer	3.38e-05	0.000961	CcSEcCtD
Vinorelbine—Hepatic failure—Methotrexate—lymphatic system cancer	3.38e-05	0.000959	CcSEcCtD
Vinorelbine—Leukopenia—Vincristine—lymphatic system cancer	3.37e-05	0.000957	CcSEcCtD
Vinorelbine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	3.36e-05	0.000954	CcSEcCtD
Vinorelbine—Chest pain—Carmustine—lymphatic system cancer	3.36e-05	0.000954	CcSEcCtD
Vinorelbine—Myalgia—Carmustine—lymphatic system cancer	3.36e-05	0.000954	CcSEcCtD
Vinorelbine—Paraesthesia—Bleomycin—lymphatic system cancer	3.31e-05	0.000941	CcSEcCtD
Vinorelbine—Malaise—Mitoxantrone—lymphatic system cancer	3.31e-05	0.000939	CcSEcCtD
Vinorelbine—Dyspnoea—Bleomycin—lymphatic system cancer	3.29e-05	0.000934	CcSEcCtD
Vinorelbine—Leukopenia—Mitoxantrone—lymphatic system cancer	3.28e-05	0.000932	CcSEcCtD
Vinorelbine—Hypertension—Vincristine—lymphatic system cancer	3.25e-05	0.000923	CcSEcCtD
Vinorelbine—Decreased appetite—Bleomycin—lymphatic system cancer	3.21e-05	0.000911	CcSEcCtD
Vinorelbine—Myalgia—Vincristine—lymphatic system cancer	3.21e-05	0.000911	CcSEcCtD
Vinorelbine—Cough—Mitoxantrone—lymphatic system cancer	3.2e-05	0.000909	CcSEcCtD
Vinorelbine—Infection—Carmustine—lymphatic system cancer	3.2e-05	0.000908	CcSEcCtD
Vinorelbine—Vomiting—Fludarabine—lymphatic system cancer	3.2e-05	0.000908	CcSEcCtD
Vinorelbine—Rash—Fludarabine—lymphatic system cancer	3.17e-05	0.000901	CcSEcCtD
Vinorelbine—Dermatitis—Fludarabine—lymphatic system cancer	3.17e-05	0.0009	CcSEcCtD
Vinorelbine—Hypertension—Mitoxantrone—lymphatic system cancer	3.17e-05	0.000899	CcSEcCtD
Vinorelbine—Pain—Bleomycin—lymphatic system cancer	3.15e-05	0.000896	CcSEcCtD
Vinorelbine—Thrombocytopenia—Carmustine—lymphatic system cancer	3.15e-05	0.000895	CcSEcCtD
Vinorelbine—Headache—Fludarabine—lymphatic system cancer	3.15e-05	0.000895	CcSEcCtD
Vinorelbine—Tachycardia—Carmustine—lymphatic system cancer	3.14e-05	0.000893	CcSEcCtD
Vinorelbine—Myalgia—Mitoxantrone—lymphatic system cancer	3.12e-05	0.000887	CcSEcCtD
Vinorelbine—Arthralgia—Mitoxantrone—lymphatic system cancer	3.12e-05	0.000887	CcSEcCtD
Vinorelbine—Chest pain—Mitoxantrone—lymphatic system cancer	3.12e-05	0.000887	CcSEcCtD
Vinorelbine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	3.1e-05	0.000879	CcSEcCtD
Vinorelbine—Lethargy—Methotrexate—lymphatic system cancer	3.1e-05	0.000879	CcSEcCtD
Vinorelbine—Discomfort—Mitoxantrone—lymphatic system cancer	3.08e-05	0.000876	CcSEcCtD
Vinorelbine—Anaphylactic shock—Vincristine—lymphatic system cancer	3.07e-05	0.000873	CcSEcCtD
Vinorelbine—Anorexia—Carmustine—lymphatic system cancer	3.07e-05	0.000872	CcSEcCtD
Vinorelbine—Infection—Vincristine—lymphatic system cancer	3.05e-05	0.000867	CcSEcCtD
Vinorelbine—Feeling abnormal—Bleomycin—lymphatic system cancer	3.04e-05	0.000863	CcSEcCtD
Vinorelbine—Nervous system disorder—Vincristine—lymphatic system cancer	3.01e-05	0.000856	CcSEcCtD
Vinorelbine—Thrombocytopenia—Vincristine—lymphatic system cancer	3.01e-05	0.000855	CcSEcCtD
Vinorelbine—Hypotension—Carmustine—lymphatic system cancer	3.01e-05	0.000855	CcSEcCtD
Vinorelbine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	2.99e-05	0.00085	CcSEcCtD
Vinorelbine—Nausea—Fludarabine—lymphatic system cancer	2.99e-05	0.000849	CcSEcCtD
Vinorelbine—Infection—Mitoxantrone—lymphatic system cancer	2.97e-05	0.000845	CcSEcCtD
Vinorelbine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	2.93e-05	0.000833	CcSEcCtD
Vinorelbine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	2.93e-05	0.000832	CcSEcCtD
Vinorelbine—Urticaria—Bleomycin—lymphatic system cancer	2.93e-05	0.000832	CcSEcCtD
Vinorelbine—Anorexia—Vincristine—lymphatic system cancer	2.93e-05	0.000832	CcSEcCtD
Vinorelbine—Tachycardia—Mitoxantrone—lymphatic system cancer	2.92e-05	0.00083	CcSEcCtD
Vinorelbine—Body temperature increased—Bleomycin—lymphatic system cancer	2.91e-05	0.000828	CcSEcCtD
Vinorelbine—Skin disorder—Mitoxantrone—lymphatic system cancer	2.91e-05	0.000826	CcSEcCtD
Vinorelbine—Paraesthesia—Carmustine—lymphatic system cancer	2.89e-05	0.000821	CcSEcCtD
Vinorelbine—Hypotension—Vincristine—lymphatic system cancer	2.87e-05	0.000816	CcSEcCtD
Vinorelbine—Dyspnoea—Carmustine—lymphatic system cancer	2.87e-05	0.000815	CcSEcCtD
Vinorelbine—Anorexia—Mitoxantrone—lymphatic system cancer	2.85e-05	0.00081	CcSEcCtD
Vinorelbine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	2.8e-05	0.000795	CcSEcCtD
Vinorelbine—Decreased appetite—Carmustine—lymphatic system cancer	2.8e-05	0.000795	CcSEcCtD
Vinorelbine—Hypotension—Mitoxantrone—lymphatic system cancer	2.8e-05	0.000794	CcSEcCtD
Vinorelbine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	2.78e-05	0.000789	CcSEcCtD
Vinorelbine—Paraesthesia—Vincristine—lymphatic system cancer	2.76e-05	0.000784	CcSEcCtD
Vinorelbine—Pain—Carmustine—lymphatic system cancer	2.75e-05	0.000782	CcSEcCtD
Vinorelbine—Constipation—Carmustine—lymphatic system cancer	2.75e-05	0.000782	CcSEcCtD
Vinorelbine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	2.73e-05	0.000775	CcSEcCtD
Vinorelbine—Hypersensitivity—Bleomycin—lymphatic system cancer	2.72e-05	0.000772	CcSEcCtD
Vinorelbine—Paraesthesia—Mitoxantrone—lymphatic system cancer	2.69e-05	0.000763	CcSEcCtD
Vinorelbine—Decreased appetite—Vincristine—lymphatic system cancer	2.67e-05	0.000759	CcSEcCtD
Vinorelbine—Dyspnoea—Mitoxantrone—lymphatic system cancer	2.67e-05	0.000758	CcSEcCtD
Vinorelbine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	2.65e-05	0.000754	CcSEcCtD
Vinorelbine—Feeling abnormal—Carmustine—lymphatic system cancer	2.65e-05	0.000754	CcSEcCtD
Vinorelbine—Fatigue—Vincristine—lymphatic system cancer	2.65e-05	0.000753	CcSEcCtD
Vinorelbine—Asthenia—Bleomycin—lymphatic system cancer	2.65e-05	0.000752	CcSEcCtD
Vinorelbine—Gastrointestinal pain—Carmustine—lymphatic system cancer	2.63e-05	0.000748	CcSEcCtD
Vinorelbine—Pain—Vincristine—lymphatic system cancer	2.63e-05	0.000747	CcSEcCtD
Vinorelbine—Constipation—Vincristine—lymphatic system cancer	2.63e-05	0.000747	CcSEcCtD
Vinorelbine—Pruritus—Bleomycin—lymphatic system cancer	2.61e-05	0.000741	CcSEcCtD
Vinorelbine—Decreased appetite—Mitoxantrone—lymphatic system cancer	2.6e-05	0.000739	CcSEcCtD
Vinorelbine—Fatigue—Mitoxantrone—lymphatic system cancer	2.58e-05	0.000733	CcSEcCtD
Vinorelbine—Pancreatitis—Methotrexate—lymphatic system cancer	2.57e-05	0.00073	CcSEcCtD
Vinorelbine—Pain—Mitoxantrone—lymphatic system cancer	2.56e-05	0.000727	CcSEcCtD
Vinorelbine—Constipation—Mitoxantrone—lymphatic system cancer	2.56e-05	0.000727	CcSEcCtD
Vinorelbine—Body temperature increased—Carmustine—lymphatic system cancer	2.54e-05	0.000723	CcSEcCtD
Vinorelbine—Abdominal pain—Carmustine—lymphatic system cancer	2.54e-05	0.000723	CcSEcCtD
Vinorelbine—Gastrointestinal pain—Vincristine—lymphatic system cancer	2.51e-05	0.000714	CcSEcCtD
Vinorelbine—Pancytopenia—Methotrexate—lymphatic system cancer	2.49e-05	0.000707	CcSEcCtD
Vinorelbine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	2.47e-05	0.000701	CcSEcCtD
Vinorelbine—Neutropenia—Methotrexate—lymphatic system cancer	2.45e-05	0.000697	CcSEcCtD
Vinorelbine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	2.45e-05	0.000695	CcSEcCtD
Vinorelbine—Abdominal pain—Vincristine—lymphatic system cancer	2.43e-05	0.00069	CcSEcCtD
Vinorelbine—Body temperature increased—Vincristine—lymphatic system cancer	2.43e-05	0.00069	CcSEcCtD
Vinorelbine—Urticaria—Mitoxantrone—lymphatic system cancer	2.38e-05	0.000675	CcSEcCtD
Vinorelbine—Hypersensitivity—Carmustine—lymphatic system cancer	2.37e-05	0.000674	CcSEcCtD
Vinorelbine—Abdominal pain—Mitoxantrone—lymphatic system cancer	2.37e-05	0.000672	CcSEcCtD
Vinorelbine—Body temperature increased—Mitoxantrone—lymphatic system cancer	2.37e-05	0.000672	CcSEcCtD
Vinorelbine—Pneumonia—Methotrexate—lymphatic system cancer	2.35e-05	0.000668	CcSEcCtD
Vinorelbine—Vomiting—Bleomycin—lymphatic system cancer	2.34e-05	0.000666	CcSEcCtD
Vinorelbine—Infestation NOS—Methotrexate—lymphatic system cancer	2.34e-05	0.000664	CcSEcCtD
Vinorelbine—Infestation—Methotrexate—lymphatic system cancer	2.34e-05	0.000664	CcSEcCtD
Vinorelbine—Rash—Bleomycin—lymphatic system cancer	2.32e-05	0.000661	CcSEcCtD
Vinorelbine—Dermatitis—Bleomycin—lymphatic system cancer	2.32e-05	0.00066	CcSEcCtD
Vinorelbine—Asthenia—Carmustine—lymphatic system cancer	2.31e-05	0.000656	CcSEcCtD
Vinorelbine—Stomatitis—Methotrexate—lymphatic system cancer	2.28e-05	0.000647	CcSEcCtD
Vinorelbine—Hypersensitivity—Vincristine—lymphatic system cancer	2.26e-05	0.000643	CcSEcCtD
Vinorelbine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	2.21e-05	0.000628	CcSEcCtD
Vinorelbine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	2.2e-05	0.000626	CcSEcCtD
Vinorelbine—Asthenia—Vincristine—lymphatic system cancer	2.2e-05	0.000626	CcSEcCtD
Vinorelbine—Diarrhoea—Carmustine—lymphatic system cancer	2.2e-05	0.000626	CcSEcCtD
Vinorelbine—Nausea—Bleomycin—lymphatic system cancer	2.19e-05	0.000622	CcSEcCtD
Vinorelbine—Agranulocytosis—Methotrexate—lymphatic system cancer	2.18e-05	0.00062	CcSEcCtD
Vinorelbine—Asthenia—Mitoxantrone—lymphatic system cancer	2.15e-05	0.00061	CcSEcCtD
Vinorelbine—Dizziness—Carmustine—lymphatic system cancer	2.13e-05	0.000605	CcSEcCtD
Vinorelbine—Diarrhoea—Vincristine—lymphatic system cancer	2.1e-05	0.000597	CcSEcCtD
Vinorelbine—Diarrhoea—Mitoxantrone—lymphatic system cancer	2.05e-05	0.000582	CcSEcCtD
Vinorelbine—Vomiting—Carmustine—lymphatic system cancer	2.05e-05	0.000581	CcSEcCtD
Vinorelbine—Dizziness—Vincristine—lymphatic system cancer	2.03e-05	0.000577	CcSEcCtD
Vinorelbine—Rash—Carmustine—lymphatic system cancer	2.03e-05	0.000577	CcSEcCtD
Vinorelbine—Dermatitis—Carmustine—lymphatic system cancer	2.03e-05	0.000576	CcSEcCtD
Vinorelbine—Headache—Carmustine—lymphatic system cancer	2.02e-05	0.000573	CcSEcCtD
Vinorelbine—Vomiting—Vincristine—lymphatic system cancer	1.95e-05	0.000555	CcSEcCtD
Vinorelbine—Cardiac disorder—Methotrexate—lymphatic system cancer	1.95e-05	0.000553	CcSEcCtD
Vinorelbine—Rash—Vincristine—lymphatic system cancer	1.94e-05	0.00055	CcSEcCtD
Vinorelbine—Dermatitis—Vincristine—lymphatic system cancer	1.94e-05	0.00055	CcSEcCtD
Vinorelbine—Headache—Vincristine—lymphatic system cancer	1.92e-05	0.000547	CcSEcCtD
Vinorelbine—Nausea—Carmustine—lymphatic system cancer	1.91e-05	0.000543	CcSEcCtD
Vinorelbine—Angiopathy—Methotrexate—lymphatic system cancer	1.9e-05	0.000541	CcSEcCtD
Vinorelbine—Vomiting—Mitoxantrone—lymphatic system cancer	1.9e-05	0.000541	CcSEcCtD
Vinorelbine—Immune system disorder—Methotrexate—lymphatic system cancer	1.9e-05	0.000539	CcSEcCtD
Vinorelbine—Mediastinal disorder—Methotrexate—lymphatic system cancer	1.89e-05	0.000537	CcSEcCtD
Vinorelbine—Rash—Mitoxantrone—lymphatic system cancer	1.89e-05	0.000536	CcSEcCtD
Vinorelbine—Dermatitis—Mitoxantrone—lymphatic system cancer	1.88e-05	0.000536	CcSEcCtD
Vinorelbine—Headache—Mitoxantrone—lymphatic system cancer	1.87e-05	0.000533	CcSEcCtD
Vinorelbine—Alopecia—Methotrexate—lymphatic system cancer	1.85e-05	0.000527	CcSEcCtD
Vinorelbine—Malnutrition—Methotrexate—lymphatic system cancer	1.83e-05	0.000519	CcSEcCtD
Vinorelbine—Erythema—Methotrexate—lymphatic system cancer	1.83e-05	0.000519	CcSEcCtD
Vinorelbine—Nausea—Vincristine—lymphatic system cancer	1.83e-05	0.000519	CcSEcCtD
Vinorelbine—Nausea—Mitoxantrone—lymphatic system cancer	1.78e-05	0.000505	CcSEcCtD
Vinorelbine—Back pain—Methotrexate—lymphatic system cancer	1.77e-05	0.000502	CcSEcCtD
Vinorelbine—Ill-defined disorder—Methotrexate—lymphatic system cancer	1.69e-05	0.000482	CcSEcCtD
Vinorelbine—Anaemia—Methotrexate—lymphatic system cancer	1.69e-05	0.00048	CcSEcCtD
Vinorelbine—Malaise—Methotrexate—lymphatic system cancer	1.65e-05	0.000468	CcSEcCtD
Vinorelbine—Vertigo—Methotrexate—lymphatic system cancer	1.64e-05	0.000466	CcSEcCtD
Vinorelbine—Leukopenia—Methotrexate—lymphatic system cancer	1.64e-05	0.000465	CcSEcCtD
Vinorelbine—Cough—Methotrexate—lymphatic system cancer	1.59e-05	0.000453	CcSEcCtD
Vinorelbine—Chest pain—Methotrexate—lymphatic system cancer	1.56e-05	0.000442	CcSEcCtD
Vinorelbine—Arthralgia—Methotrexate—lymphatic system cancer	1.56e-05	0.000442	CcSEcCtD
Vinorelbine—Myalgia—Methotrexate—lymphatic system cancer	1.56e-05	0.000442	CcSEcCtD
Vinorelbine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	1.54e-05	0.000439	CcSEcCtD
Vinorelbine—Discomfort—Methotrexate—lymphatic system cancer	1.54e-05	0.000437	CcSEcCtD
Vinorelbine—Anaphylactic shock—Methotrexate—lymphatic system cancer	1.49e-05	0.000424	CcSEcCtD
Vinorelbine—Infection—Methotrexate—lymphatic system cancer	1.48e-05	0.000421	CcSEcCtD
Vinorelbine—Nervous system disorder—Methotrexate—lymphatic system cancer	1.46e-05	0.000415	CcSEcCtD
Vinorelbine—Thrombocytopenia—Methotrexate—lymphatic system cancer	1.46e-05	0.000415	CcSEcCtD
Vinorelbine—Skin disorder—Methotrexate—lymphatic system cancer	1.45e-05	0.000411	CcSEcCtD
Vinorelbine—Anorexia—Methotrexate—lymphatic system cancer	1.42e-05	0.000404	CcSEcCtD
Vinorelbine—Hypotension—Methotrexate—lymphatic system cancer	1.39e-05	0.000396	CcSEcCtD
Vinorelbine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	1.36e-05	0.000386	CcSEcCtD
Vinorelbine—Paraesthesia—Methotrexate—lymphatic system cancer	1.34e-05	0.00038	CcSEcCtD
Vinorelbine—Dyspnoea—Methotrexate—lymphatic system cancer	1.33e-05	0.000378	CcSEcCtD
Vinorelbine—Decreased appetite—Methotrexate—lymphatic system cancer	1.3e-05	0.000368	CcSEcCtD
Vinorelbine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	1.29e-05	0.000366	CcSEcCtD
Vinorelbine—Fatigue—Methotrexate—lymphatic system cancer	1.29e-05	0.000365	CcSEcCtD
Vinorelbine—Pain—Methotrexate—lymphatic system cancer	1.27e-05	0.000362	CcSEcCtD
Vinorelbine—Feeling abnormal—Methotrexate—lymphatic system cancer	1.23e-05	0.000349	CcSEcCtD
Vinorelbine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	1.22e-05	0.000346	CcSEcCtD
Vinorelbine—Urticaria—Methotrexate—lymphatic system cancer	1.18e-05	0.000336	CcSEcCtD
Vinorelbine—Abdominal pain—Methotrexate—lymphatic system cancer	1.18e-05	0.000335	CcSEcCtD
Vinorelbine—Body temperature increased—Methotrexate—lymphatic system cancer	1.18e-05	0.000335	CcSEcCtD
Vinorelbine—Hypersensitivity—Methotrexate—lymphatic system cancer	1.1e-05	0.000312	CcSEcCtD
Vinorelbine—Asthenia—Methotrexate—lymphatic system cancer	1.07e-05	0.000304	CcSEcCtD
Vinorelbine—Pruritus—Methotrexate—lymphatic system cancer	1.05e-05	0.0003	CcSEcCtD
Vinorelbine—Diarrhoea—Methotrexate—lymphatic system cancer	1.02e-05	0.00029	CcSEcCtD
Vinorelbine—Dizziness—Methotrexate—lymphatic system cancer	9.86e-06	0.00028	CcSEcCtD
Vinorelbine—Vomiting—Methotrexate—lymphatic system cancer	9.48e-06	0.000269	CcSEcCtD
Vinorelbine—Rash—Methotrexate—lymphatic system cancer	9.4e-06	0.000267	CcSEcCtD
Vinorelbine—Dermatitis—Methotrexate—lymphatic system cancer	9.39e-06	0.000267	CcSEcCtD
Vinorelbine—Headache—Methotrexate—lymphatic system cancer	9.34e-06	0.000265	CcSEcCtD
Vinorelbine—Nausea—Methotrexate—lymphatic system cancer	8.86e-06	0.000252	CcSEcCtD
